產品
Moderna and Merck cancer vaccine wins in late-stage trial
Moderna and Merck & Co.'s jointly developed individualized cancer vaccine reported a positive result in a late-stage trial, per the article. The readout is for the mRNA cancer-vaccine program the two companies co-develop, and follow-on coverage in the same sweep tied it to melanoma. No efficacy figures are given in the cited piece, so none are reproduced here.
文章預覽
Moderna (MRNA), Merck (MRK) Cancer Vaccine Wins in Late-Stage Trial Fatima Gulzar Sat, August 29, 2026 at 2:16 AM GMT+10 4 min read MRNA MRK On August 19, 2026, Moderna, Inc. (NASDAQ: MRNA ) and Merck & Co., Inc. (NYSE: MRK ) said their personalized melanoma vaccine, intismeran, combined with Merck's Keytruda, met its goals in a Phase 3 trial of 1,137 patients. It reduced the risk of cancer recurrence and spread compared with Keytruda alone, Reuters reported. It is the first positive late-stage trial result for an mRNA cancer vaccine. Merck's Jane Healy called the result a "clinically meaningf…